All In Biotech

Drug Trial Radar · NCT03345979

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation

Last checked: Nov 20, 2026Latest source record: Aug 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Nov 15, 2017

Primary completion

Mar 12, 2019

Study completion Mar 12, 2019

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.

Conditions

  • Schizophrenia

Interventions

  • Aripiprazole LauroxilCombination product

    Intramuscular injection; study drug provided using a pre-filled syringe

  • Paliperidone PalmitateDrug

    Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4Time frame: Baseline and 4 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Little Rock, Arkansas

  • Alkermes Investigational Site

    Rogers, Arkansas

  • Alkermes Investigational Site

    Cerritos, California

  • Alkermes Investigational Site

    Culver City, California

  • Alkermes Investigational Site

    Garden Grove, California

  • Alkermes Investigational Site

    Lemon Grove, California

  • Alkermes Investigational Site

    Hialeah, Florida

  • Alkermes Investigational Site

    Chicago, Illinois

  • Alkermes Investigational Site

    Hoffman Estates, Illinois

  • Alkermes Investigational Site

    Flowood, Mississippi

  • Alkermes Investigational Site

    St Louis, Missouri

  • Alkermes Investigational Site

    Las Vegas, Nevada

  • Alkermes Investigational Site

    Berlin, New Jersey

  • Alkermes Investigational Site

    Austin, Texas

  • Alkermes Investigational Site

    Garland, Texas

  • Alkermes Investigational Site

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.